Crossmark

Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer

Crossref DOI link: https://doi.org/10.1038/s41598-026-57604-0

Published Online: 2026-06-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Al-Qahtani, Mohammed H. https://orcid.org/0009-0002-8237-9079
Jafri, Mohammad Alam

Assidi, Mourad

Buhmeida, Abdelbaset

Pushparaj, Peter Natesan

Abdullah, Maha Khalid

Alganmi, Nofe Ateq
Funding

Funding for this research was provided by:

Ministry of Education in Saudi Arabia (grant number 886)
License Information

Text and Data Mining valid from 2026-06-18

Accepted Manuscript valid from 2026-06-18
More Information

Article History

Received: 10 March 2026

Accepted: 8 June 2026

First Online: 18 June 2026

Declarations

:

: The ethical obligations are not applicable as the study is computational.

: All authors consent to submit the manuscript to this Journal.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below